QualityStocks.net News – RXi Pharmaceuticals Corp. (RXII) Added to the Russell Microcap Index

We would like to highlight RXi Pharmaceuticals Corp. (NASDAQ: RXII). The company is a discovery-stage biopharmaceutical company pursuing the development and potential commercialization of therapeutics based on ribonucleic acid interference (RNAi) for the treatment of human diseases. The Company's initial focus is on the treatment of neurological diseases, metabolic diseases and oncology.

In the company’s recent news,

RXi Pharmaceuticals announced that it has been added to the Russell Microcap Index as part of Russell Investments’ annual reconstitution of its family of U.S. indexes. Russell indexes are a commonly used tool among investment managers and institutional investors as a benchmark, helping to distinguish passive and active investments.

The Russell indexes capture the 4,000 largest domestic stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000 Index and the Russell Microcap Index. RXi Pharmaceutical’s new membership to the Russell Microcap Index will remain in place for one year until the 4,000 stocks are reevaluated May 31st of the following year. Becoming a member of the index ensures a greater exposure to institutional investors, as well as constant comparison to other industry players.

President and CEO of RXi Pharmaceuticals, Dr. Tod Woolf, said of the announcement, “We are pleased that we have been added to the Russell Microcap Index. We believe that the exposure gained from our listing has the potential to increase our visibility within the investment community.” The Russell Indexes have been a common benchmark for investors since their creation in the 1980’s as a tool to evaluate investment managers.

The entire team at RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi market. It has a strong technology platform, broad and early intellectual property position, and a management team that is experienced in commercializing products. The company also has the luxury of having a knowledgeable and accomplished board of scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.